A Placebo-controlled Study to Investigate Safety and Efficacy of BIA 2-093

NCT02170077 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

144

Enrollment

INDUSTRY

Sponsor class

Conditions

Epilepsy

Interventions

DRUG: BIA 2-093
DRUG: Placebo

Sponsor

Bial - Portela C S.A.